Clinical Trial

Stemtech Announces China Market Expansion

Stemtech Unveils Bold Vision ‘Grand China Market Plan' to Supercharge China's Thriving Health and Wellness Landscape Amidst $ 683 Billion…

11 months ago

Jaguar Health Reports Second Quarter 2023 Financial Results

Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3…

11 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed…

11 months ago

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for…

11 months ago

Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research…

11 months ago

H1 Launches H1 Mobile App to Empower Medical Affairs with Real-Time KOL Insights and Expertise on the Go

MSLs can now leverage the power of HCP Universe anywhere, at any time to enhance interactions with healthcare leadersNEW YORK,…

11 months ago

IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023…

11 months ago

Allogene Therapeutics Appoints Earl Douglas as General Counsel

Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),…

11 months ago

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…

11 months ago

SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis

JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive…

11 months ago